National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix E: Prospects for Immunizing Against Cytomegalovirus." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
198
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Appendix E
PROSPECTS FOR IMMUNIZING AGAINST CYTOMEGALOVIRUS

Disease Description

Human cytomegalovirus (CMV) does not cause identifiable disease in the vast majority of infections. The major problems result from congenital cytomegalovirus infection. Only 5 to 10 percent of congenital infections are symptomatic, but 1 to 2 percent of these are fatal. Almost 90 percent of symptomatic infections leave sequelae in the survivors. Between 5 and 17 percent of congenitally infected children who are asymptomatic at birth have late sequelae. The acute manifestations of congenital cytomegalovirus infection include hepatic disease, resulting in jaundice, and multiorgan involvement including ocular and cerebral infections (Weller, 1971).

Cytomegalovirus infection also can be acquired in the newborn period, through inoculation of virus from the birth canal during delivery or by ingestion of infected breast milk (Stagno et al., 1980). The disease spectrum associated with perinatal infection has not been well defined, but appears to be less serious than that of congenital infections, although children may develop delayed complications.

Acute infection in a normal host induces antibodies and a specific cell-mediated immune response, but viral shedding may persist for months or even years, and the virus may become latent. Reactivation of CMV infection with viral shedding may occur in asymptomatic patients.

Symptomatic illness after early childhood, resulting from reactivation of the virus or primary infection, usually occurs in immunocompromised hosts. Cytomegalovirus pneumonia and other manifestations may be especially severe and are often fatal in patients who have undergone bone marrow transplants and other procedures that require suppression of the immune system.

The advice and assistance of C.Alford, J.B.Hanshaw, D.Medearis, J. Osborn, S.Plotkin, S.Stagno, and J.Stewart in the preparation of this appendix are gratefully acknowledged. The committee assumes full responsibility for any judgments or assumptions.

Page
198
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 198

OCR for page 199

OCR for page 200

OCR for page 201

OCR for page 202

OCR for page 203

OCR for page 204

OCR for page 205

OCR for page 206

OCR for page 207

OCR for page 208

OCR for page 224

OCR for page 225

OCR for page 226

OCR for page 227

OCR for page 228

OCR for page 229

OCR for page 230

OCR for page 231

OCR for page 232

OCR for page 233

OCR for page 234